clinical trial · NCT06932107
Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting
Qilu Pharmaceutical (Hainan) Co., Ltd.·phase3·completed·n = 518
Postoperative Nausea and VomitingAprepitant InjectionAprepitant Injection Placebo
brief summary
The goal of this Interventional study is to evaluate the efficacy and safety of Aprepitant Injection(QLG2174) for preventing PONV in Chinese patients.
started
Feb 2, 2024
primary completion
May 28, 2024
completion
Jun 5, 2024
last updated
Apr 23, 2025
official title
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection(QLG2174) in the Prevention of Post-operative Nausea and Vomiting
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol